1. Home
  2. ENGN vs LX Comparison

ENGN vs LX Comparison

Compare ENGN & LX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

SELL

Current Price

$1.95

Market Cap

117.2M

Sector

N/A

ML Signal

SELL

Logo LexinFintech Holdings Ltd.

LX

LexinFintech Holdings Ltd.

SELL

Current Price

$0.57

Market Cap

102.7M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ENGN
LX
Founded
1999
2013
Country
Canada
China
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
117.2M
102.7M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
ENGN
LX
Price
$1.95
$0.57
Analyst Decision
Buy
Buy
Analyst Count
9
5
Target Price
★ $4.29
$2.13
AVG Volume (30 Days)
★ 1.5M
873.8K
Earning Date
12-21-2026
11-27-2026
Dividend Yield
N/A
★ 61.31%
EPS Growth
★ 56.85
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$2.08
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$0.59
52 Week High
$12.25
$3.98

Technical Indicators

Market Signals
Indicator
ENGN
LX
Relative Strength Index (RSI) 55.31 37.28
Support Level $1.61 N/A
Resistance Level $8.93 $0.74
Average True Range (ATR) 0.18 0.05
MACD 0.07 0.00
Stochastic Oscillator 47.17 5.40

Price Performance

Historical Comparison
ENGN
LX

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

About LX LexinFintech Holdings Ltd.

LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.

Share on Social Networks: